Cleveland Clinic Neurological Institute-Neurology, Center for Headache and Pain, Center for Regional Neurology, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Headache. 2012 May;52(5):739-48. doi: 10.1111/j.1526-4610.2011.02059.x. Epub 2011 Dec 28.
Predicting who will develop post-procedure headache (PPH) following intracranial endovascular procedures (IEPs) would be clinically useful and potentially could assist in reducing the excessive diagnostic testing so often obtained in these patients. Although limited safety data exist, the use of triptans or dihydroergotamine (DHE) often raise concern when used with pre/post-coiled aneurysms. We sought to determine risk factors for PPH following IEP, to evaluate the utility of diagnostic testing in patients with post-coil acute headache (HA), and to record whether triptans and DHE have been used safely in this clinical setting.
We conducted a retrospective chart review of adult patients undergoing IEPs. Bivariate analyses were conducted to compare patients who did and did not develop PPH.
We reviewed records pertaining to 372 patients, of whom 263 underwent intracranial coil embolizations, 21 acrylic glue embolizations, and 88 stent placements. PPH occurred in 72% of coil patients, 33% of glue patients, and 14% of stent patients. Significant risk factors for post-coil HA were female gender, any pre-coil HA history, smoking, and anxiety/depression. A pre-stent history of HA exceeding 1 year's duration, and smoking were risk factors for post-stent HA. A pre-glue history of HA exceeding 1 year was the only risk factor for post-glue HA. In the small subgroup available for study, treatment with triptans or DHE was not associated with adverse events in pre/post-coiled aneurysms. Diagnostic testing was low yield.
Occurrence of PPH was common after IEPs and especially so with coiling and in women, smokers, and those with anxiety/depression, and was often of longer duration than allowed by current International Classification of Headache Disorders-II criteria. The yield of diagnostic testing was low, and in a small subgroup treatment with triptans or DHE did not cause adverse events in pre/post-coiled aneurysms. Prospective studies are needed to confirm these findings.
预测颅内血管内介入治疗(IEP)后哪些患者会发生术后头痛(PPH)具有重要的临床意义,这可能有助于减少这些患者过度的诊断性检查。虽然有限的安全性数据存在,但曲坦类药物或二氢麦角胺(DHE)在治疗伴有术前/术后线圈的动脉瘤时,通常会引起人们的关注。我们旨在确定 IEP 后发生 PPH 的危险因素,评估在 coil 后急性头痛(HA)患者中进行诊断性检查的效用,并记录在这种临床情况下曲坦类药物和 DHE 是否安全使用。
我们对接受 IEP 的成年患者进行了回顾性图表审查。采用双变量分析比较了发生和未发生 PPH 的患者。
我们回顾了 372 例患者的记录,其中 263 例接受颅内线圈栓塞术,21 例接受丙烯酸胶栓塞术,88 例接受支架置入术。 coil 组患者中有 72%发生 PPH,胶组患者中有 33%,支架组患者中有 14%。 coil 后 HA 的显著危险因素为女性、任何术前 HA 病史、吸烟和焦虑/抑郁。支架后 HA 的危险因素为支架前 HA 病史超过 1 年,以及吸烟。胶后 HA 的唯一危险因素是胶前 HA 病史超过 1 年。在可用于研究的小亚组中,在 coil 前/后动脉瘤中使用曲坦类药物或 DHE 与不良事件无关。诊断性检查的结果阳性率较低。
IEP 后 PPH 的发生率较高, coil 后尤其如此,女性、吸烟者、焦虑/抑郁患者的发生率更高,且持续时间通常比当前国际头痛疾病分类标准 II 允许的时间长。诊断性检查的阳性率较低,在一个小亚组中,曲坦类药物或 DHE 的治疗在 coil 前/后动脉瘤中未引起不良事件。需要前瞻性研究来证实这些发现。